Gene-based vaccines: recent technical and clinical advances

Trends in Molecular Medicine

Volumn 12, Issue 5, 2006, Pages 216-222

  Ulmer, Jeffrey B ^a   Wahren, Britta ^b   Liu, Margaret A ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c TRANSGENE S A   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE;

ALLERGY; AUTOIMMUNE DISEASE; CANCER; CELL TRANSPORT; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION; INNATE IMMUNITY; INTERCELLULAR SPACE; LICENSING; NONHUMAN; REVIEW;

ANIMALS; ANTIGENS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HUMANS; IMMUNITY, INNATE; IMMUNITY, NATURAL; PROTEIN TRANSPORT; VACCINES, DNA;

ANIMALIA; EQUUS CABALLUS;

EID: 33646568454     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.03.007     Document Type: Review

References (48)

1. Wang, S. et al. (2005) Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine, DOI:10.1016/j.vaccine.2005.08.023
2. Otten, G.R. et al. (2006) Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine, in press
3. Bins A.D., et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat. Med. 11 (2005) 899-904
4. Buchan S., et al. Electroporation as a 'prime/boost' strategy for naked DNA vaccination against a tumor antigen. J. Immunol. 174 (2005) 6292-6298
5. Otten G.R., et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J. Virol. 79 (2005) 8189-8200
6. Hermanson G., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13601-13606
7. Kim T.W., et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum. Gene Ther. 15 (2004) 167-177
8. Perkins S.D., et al. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. Vaccine 23 (2005) 1931-1940
9. Zheng C., et al. Bovine herpesvirus 1 VP22 enhances the efficacy of a DNA vaccine in cattle. J. Virol. 79 (2005) 1948-1953
10. + T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection. J. Leukoc. Biol. 78 (2005) 401-411
11. Coban C., et al. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J. Leukoc. Biol. 78 (2005) 647-655
12. Li S., et al. Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol. Ther. 11 (2005) 112-119
13. Kutzler M.A., et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J. Immunol. 175 (2005) 112-123
14. Zhou H., et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10846-10851
15. Zuber A.K., et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 22 (2004) 1791-1798
16. Smorlesi A., et al. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther. 12 (2005) 1324-1332
17. Charo J., et al. Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug. J. Virol. 78 (2004) 11321-11326
18. Rottinghaus S.T., et al. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21 (2003) 4604-4608
19. Dyer C.M., et al. Unexpectedly, induction of cytotoxic T lymphocytes enhances the humoral response after DNA immunization. Blood 103 (2004) 3073-3075
20. + T-cell immune response. J. Biomed. Sci. 11 (2004) 493-499
21. Chattergoon M.A., et al. Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered fas-mediated apoptosis. Nat. Biotechnol. 18 (2000) 974-979
22. Li A.F., et al. Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice. Vaccine 22 13-14 (2004) 1751-1763
23. Epstein S.L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23 46-47 (2005) 5404-5410
24. Ferraz J.C., et al. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect. Immun. 72 (2004) 6945-6950
25. Wang J., et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173 (2004) 6357-6365
26. Haygreen L., et al. DNA vaccines for poultry: the jump from theory to practice. Expert Rev. Vaccines 4 (2005) 51-62
27. Lillehoj H.S., et al. Resistance to intestinal coccidiosis following DNA immunization with the cloned 3-1E Eimeria gene plus IL-2, IL-15, and IFN-γ. Avian Dis. 49 (2005) 112-117
28. MacGregor R.R., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178 (1998) 92-100
29. Dale C.J., et al. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J. Virol. 78 (2004) 13819-13828
30. Smith J.M., et al. Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses. AIDS Res. Hum. Retroviruses 21 (2005) 140-144
31. MacGregor R.R., et al. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral 'blips'. Vaccine 23 17-18 (2005) 2066-2073
32. Hejdeman B., et al. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses 20 (2004) 860-870
33. Mascola J.R., et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 79 (2005) 771-779
34. Brave A., et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol. Ther. 12 (2005) 1197-1205
35. Wang R., et al. Boosting of DNA vaccine-elicited γ interferon responses in humans by exposure to malaria parasites. Infect. Immun. 73 (2005) 2863-2872
36. Le T.P., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18 (2000) 1893-1901
37. Wang R., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 (1998) 476-480
38. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4 (1998) 397-402
39. McConkey S.J., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729-735
40. Webster D.P., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4836-4841
41. Triozzi P.L., et al. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J. Immunother. 28 (2005) 382-388
42. Stevenson F.K., et al. DNA vaccines to attack cancer. Proc Natl Acad Sci U. S. A. 101 Suppl. 2 (2004) 14646-14652
43. Rice J., et al. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. J. Immunol. 173 (2004) 4492-4499
44. Pavlenko M., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer 91 (2004) 688-694
45. Powell K. DNA vaccines - back in the saddle again?. Nat. Biotechnol. 22 (2004) 799-801
46. Lorenzen N., and LaPatra S.E. DNA vaccines for aquacultured fish. Rev. Sci. Tech. 24 (2005) 201-213
47. Ramos E.A., et al. Gene expression in tilapia following oral delivery of chitosan-encapsulated plasmid DNA incorporated into fish feeds. Mar. Biotechnol. 7 (2005) 89-94
48. Kurath G. Overview of recent DNA vaccine development for fish. Dev. Biol. (Basel) 121 (2005) 201-213